EUVIMEDEUVIMED entdecken
Open Access

HER2 Antibody–Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody–Drug Conjugates

Jingyi Qiu, Yasin Alp, Shuai Gong iD, Paige Szipszky, D Joseph Jerry, S Thayumanavan iD

Nano Letters · 14.01.2026 · 26 (1) · 246-253

DOI: 10.1021/acs.nanolett.5c04911 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, online erschienen am 23.12.2025. Verfasst von Jingyi Qiu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Massachusetts, Amherst, Massachusetts 01003, United States. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates, Breast Neoplasms, Nanogels. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

HER2-targeted antibody-nanogel conjugates (ANCs) were developed with covalently encapsulated DM1 and benchmarked against the clinically optimized antibody-drug conjugate Kadcyla (T-DM1). In vitro, ANCs showed cytotoxicity comparable to that of T-DM1. In vivo, despite being at the proof-of-concept stage, HER2-DM1-ANC achieved equivalent antitumor efficacy in a BT-474 breast cancer xenograft model while requiring 4-fold less antibody. This reduced antibody usage may lessen the risk of tumor resistance, highlighting the unique advantage of the nanogel platform. The benefit stems from ANCs' higher drug-to-antibody ratio, achieved without chemical modification of the payload─a key bottleneck in ADC development. While T-DM1 represents a mature clinical product, these findings underscore ANCs as a high-capacity, modular nanoscale platform with significant potential for refinement and optimization in antibody-directed therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesBreast NeoplasmsNanogelsMaytansineHumansAnimalsFemaleMiceCell Line, TumorXenograft Model Antitumor AssaysAdo-Trastuzumab EmtansineTrastuzumab

Stichwörter der Autor:innen

HER2-targeted therapyantibody−drug conjugatesantibody−nanogel conjugatesbreast cancerdrug deliveryxenograft model

Substanzen

Erb-b2 Receptor Tyrosine KinasesImmunoconjugatesNanogelsAdo-Trastuzumab EmtansineMaytansineTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Massachusetts, Amherst, Massachusetts 01003, United States.
  • Center for Bioactive Delivery, Institute for Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, United States.
  • Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, United States.
  • Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, Massachusetts 01003, United States.

ORCID-Profile: Shuai Gong, S Thayumanavan

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Qiu, J., Alp, Y., Gong, S., Szipszky, P., Jerry, D. J., & Thayumanavan, S. (2026). HER2 Antibody–Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody–Drug Conjugates. Nano Letters, 26(1), 246-253. https://doi.org/10.1021/acs.nanolett.5c04911

Vancouver

Qiu J, Alp Y, Gong S, Szipszky P, Jerry DJ, Thayumanavan S. HER2 Antibody–Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody–Drug Conjugates. Nano Letters. 2026;26(1):246-253. doi:10.1021/acs.nanolett.5c04911

BibTeX
@article{Qiu2026,
  author = {Qiu, Jingyi and Alp, Yasin and Gong, Shuai and Szipszky, Paige and Jerry, D Joseph and Thayumanavan, S},
  title = {HER2 Antibody–Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody–Drug Conjugates},
  journal = {Nano Letters},
  year = {2026},
  volume = {26},
  number = {1},
  pages = {246--253},
  doi = {10.1021/acs.nanolett.5c04911}
}
Kostenlos starten →